This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the current standard of care for Alpha-1 antitrypsin deficiency and the potential of Mereo BioPharma's alvelestat.

Ticker(s): MREO

Who's the expert?

Institution: AMITA Health

  • Attending ICU Physician
  • manages treatment for several patients with PAH 
  • has prescribed Tyvaso for 2 patients and is familiar with Tyvaso DPI

Interview Goal
mreo

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.